Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Sucampo Pharma Inc (SCMP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 721,930
  • Shares Outstanding, K 45,830
  • Annual Sales, $ 153,180 K
  • Annual Income, $ 33,370 K
  • 36-Month Beta 1.74
  • Price/Sales 4.71
  • Price/Book 4.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.30 +32.12%
on 11/08/16
17.55 -14.93%
on 11/30/16
+3.28 (+28.15%)
since 11/07/16
3-Month
10.60 +40.85%
on 11/02/16
17.55 -14.93%
on 11/30/16
+2.90 (+24.11%)
since 09/07/16
52-Week
9.59 +55.68%
on 03/17/16
18.75 -20.37%
on 12/23/15
-1.05 (-6.57%)
since 12/07/15

Most Recent Stories

More News
Why Valeant Pharmaceuticals (VRX) Could Be Positioned for a Slump

Valeant Pharmaceuticals International (VRX) has witnessed a significant price decline and negative trend in earnings estimate revisions

5 Stocks to Buy for Remarkable Earnings Growth in 2017

Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price

The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group

The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group

Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

Theravance Stock Up on Fast Track Status for Velusetrag

Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.

5 Best Small-Cap Stocks for 2017

Investing in small cap stocks with superior fundamentals will make for a profitable choice even in 2017.

Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

Acceleron, Celgene Present Myelodysplastic Syndromes Data

Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones...

See More

Support & Resistance

2nd Resistance Point 16.21
1st Resistance Point 15.57
Last Price 14.93
1st Support Level 14.47
2nd Support Level 14.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.